Nanocurcumin: preparation, characterization and cytotoxic effects towards human laryngeal cancer cells. Issue 35 (1st June 2020)

• Record Type: Journal Article
• Authors: Hanna, Demiana H.; Saad, Gamal R.
• Is Part Of: RSC advances. Volume 10:Issue 35(2020)
• Page Start: 20724
• Page End: 20737
• Publication Date: 2020-06-01
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d0ra03719b
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : The aim of this study was to prepare curcumin nanoparticles using a sol–oil method to improve curcumin absorption and bioavailability, and to investigate the therapeutic effect of the prepared nanoparticles on the inhibition mechanisms toward human Hep-2 cancer cells. Abstract : The aim of the present study was to prepare curcumin nanoparticles (nanocurcumin) by a sol-oil method to improve curcumin absorption and bioavailability, and to investigate the therapeutic effects of the prepared nanoparticles on the inhibition mechanisms towards human Hep-2 cancer cells. The nanoparticles were characterized by Fourier transform infrared spectroscopy, transmission electron microscopy, X-ray diffraction, and zeta potential analysis. The prepared curcumin nanoparticles possessed a narrow particle size distribution with an average diameter of 28 nm. The inhibition effects on the growth of human Hep-2 cells were investigated using neutral red uptake and lactate dehydrogenase assays. The results indicated that the nanocurcumin has a selective effect in inhibiting Hep-2 cell growth in a dose- and time-dependent mode with the most effective IC50 value (17 ± 0.31 μg ml −1 ) obtained after 48 h of incubation without any cytotoxic effects on normal cells. This IC50 value of nanocurcumin revealed a significant increase of early and late apoptotic cells with an intense comet nucleus of Hep-2 cells as a marker of DNA damage. Flow cytometry analysis of the progression of apoptosis in nanocurcumin Hep-2 treated cells showed that arresting in the cell cycle in the G2/M phase with increasing apoptotic cells in the sub-G1 phase. At the same time, real-time PCR analysis indicated that the treatment of Hep-2 cells with nanocurcumin resulted in upregulation of P53, Bax, and Caspase-3, whereas there was downregulation of Bcl-XL. These findings gave insights into understanding that the inhibition mechanisms of nanocurcumin on the proliferation of Hep-2 cancer cells was through the G2/M cell cycle arrest and the induction of apoptosis was dependent on Caspase-3 and p53 activation. However, in vivo studies with an animal model are essential to validate these results.